News for C4 Therapeutics, Inc. (CCCC)

**media[587774]**

C4 Therapeutics shows promise in protein degraders but faces safety concerns and long timelines. Click here to find out why I rate CCCC stock a Hold.

C4 Therapeutics (CCCC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

The heavy selling pressure might have exhausted for C4 Therapeutics (CCCC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

C4 Therapeutics (CCCC) delivered earnings and revenue surprises of -11.36% and 39.45%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Revenue: $5.2 million for Q4 2024, slightly above the estimated $5.13 million, driven by new collaborations.Annual Revenue: $35.6 million for 2024, slightly be

**media[552070]**

Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin's Lymphoma; Trials Expected to Initiate i

The heavy selling pressure might have exhausted for C4 Therapeutics (CCCC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

**media[548338]**

WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) ( CCCC), a clinical-stage biopharmaceutical company dedicated to advancing tar

On December 31, 2024, Lynx1 Capital Management LP (Trades, Portfolio) made a significant move by acquiring an additional 4,672,349 shares of Allogene Therapeuti

Overview of the Recent Transaction On December 31, 2024, Lynx1 Capital Management LP (Trades, Portfolio) executed a notable transaction by acquiring 766,051 sha

**media[514511]**

**media[509154]**

C4 Therapeutics (CCCC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

On November 27, 2024, Lynx1 Capital Management LP (Trades, Portfolio) made a significant move by acquiring an additional 456,353 shares of Passage Bio Inc (NASD

**media[471316,471319]**